Last update 01 Nov 2024

Alexion Europe SAS

Subsidiary Company|
2014|
France

Overview

Tags

Other Diseases
Hemic and Lymphatic Diseases
Congenital Disorders
Monoclonal antibody
Fusion protein
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases4
Immune System Diseases3
Endocrinology and Metabolic Disease3
Neoplasms2
Nervous System Diseases2
Infectious Diseases2
Top 5 Drug TypeCount
Monoclonal antibody3
Small molecule drug1
Fusion protein1
Enzyme1
Top 5 TargetCount
C5(Complement C5)2
IL-5(Interleukin-5)1
Alkaline phosphatase1
LIPA(lipase A, lysosomal acid type)1
CFD(Complement factor D)1

Related

6
Drugs associated with Alexion Europe SAS
Danicopan
Target
CFD
Mechanism
CFD inhibitors
Active Org.
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc. [+4]
Originator Org.
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
Active Indication
Hemoglobinuria, Paroxysmal [+3]
Inactive Indication
C3 glomerulopathy [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date18 Jan 2024
Ravulizumab-CWVZ
Target
C5
Mechanism
C5 inhibitors
Active Org.
Alexion Europe SAS [+8]
Originator Org.
Alexion Pharmaceuticals, Inc.Alexion Pharmaceuticals, Inc.
Active Indication
Neuromyelitis Optica [+13]
Inactive Indication
Acute Lung Injury [+4]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date21 Dec 2018
Reslizumab
Target
IL-5
Mechanism
IL-5 inhibitors
Active Org.
Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd. [+6]
Originator Org.
UCB SAUCB SA
Active Indication
Pulmonary Eosinophilia [+2]
Inactive Indication
airway disease [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date23 Mar 2016
2
Clinical Trials associated with Alexion Europe SAS
CTR20230681 / Active, not recruitingPhase 3
非典型溶血性尿毒症综合征（aHUS）儿童和成人受试者中评估依库珠单抗的疗效、安全性、药代动力学、药效学和免疫原性的前瞻性、单臂、多中心研究
[Translation] A prospective, single-arm, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of eculizumab in children and adults with atypical hemolytic uremic syndrome (aHUS)
CTR20230832 / Active, not recruitingPhase 3
一项在中国首次接受补体抑制剂治疗的阵发性睡眠性血红蛋白尿（PNH）成人受试者中评估依库珠单抗的疗效、安全性、药代动力学、药效学和免疫原性的开放性多中心研究
[Translation] An open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of eculizumab in Chinese adult subjects with paroxysmal nocturnal hemoglobinuria (PNH) who were first treated with complement inhibitors
100 Clinical Results associated with Alexion Europe SAS
Login to view more data
0 Patents (Medical) associated with Alexion Europe SAS
Login to view more data
100 Deals associated with Alexion Europe SAS
Login to view more data
100 Translational Medicine associated with Alexion Europe SAS
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
1
5
Approved
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free